ProCE Banner Activity

Integrating New Agents to Optimize Multiple Myeloma Care: Expert Answers to Frequently Asked Questions

Text Module

Expert answers to frequently asked questions about new agents for the treatment of multiple myeloma, including recently approved therapies and those on the horizon with the potential to change clinical practice.

Released: March 09, 2018

Expiration: March 08, 2019

No longer available for credit.

Share

Faculty

Melissa Alsina

Melissa Alsina, MD

Head, Multiple Myeloma BMT Program
H. Lee Moffitt Cancer Center & Research Institute
Tampa, Florida

Suzanne Lentzsch

Suzanne Lentzsch, MD, PhD

Director, Multiple Myeloma and Amyloidosis Program
Associate Professor of Medicine
Division of Hematology/Oncology
Columbia University Medical Center
New York, New York

Ajai Chari

Ajai Chari, MD

Director of Multiple Myeloma Program
Professor of Clinical Medicine
University of California- San Francisco
San Francisco, California

Raymond L. Comenzo

Raymond L. Comenzo, MD

Director, Blood Bank and Stem Cell Processing Laboratory
Tufts Medical Center
Professor of Medicine and Pathology
Tufts University School of Medicine
Boston, Massachusetts

Jonathan L. Kaufman

Jonathan L. Kaufman, MD

Assistant Professor
Winship Cancer Institute
Emory University
Atlanta, Georgia

Amrita Krishnan

Amrita Krishnan, MD, FACP

Director 
Judy Bernard Briskin Center for Myeloma
Executive Director
Professor
Hematology City of Hope Irvine
Duarte, California

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC

ProCE Banner

Supporters

This activity is supported by educational grants from

Celgene

Karyopharm Therapeutics

Takeda Oncology

Target Audience

This program is intended for physicians, registered nurses, pharmacists, and other healthcare professionals who care for patients with multiple myeloma.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Integrate the newly approved monoclonal antibodies daratumumab and elotuzumab into existing treatment strategies for patients with myeloma
  • Describe laboratory testing interference and potential strategies to assess response to therapy when using monoclonal antibodies to treat patients with myeloma
  • Plan appropriate treatment strategies using the new-generation proteasome inhibitors carfilzomib and ixazomib for individual patients with myeloma
  • Apply data recently presented at major hematology/medical oncology meetings to clinical practice
  • Develop a proactive management plan for adverse events associated with new agents used to treat myeloma

Program Director Disclosure

Program Director

Melissa Alsina, MD

Head, Multiple Myeloma BMT Program
H. Lee Moffitt Cancer Center & Research Institute
Tampa, Florida

Melissa Alsina, MD, has disclosed that she has received consulting fees from Bristol-Myers Squibb, fees for non-CME/CE services received directly from a commercial interest or their agents (eg, speaker bureaus) from Amgen and Janssen, and funds for research support from Amgen.

Suzanne Lentzsch, MD, PhD

Director, Multiple Myeloma and Amyloidosis Program
Associate Professor of Medicine
Division of Hematology/Oncology
Columbia University Medical Center
New York, New York

Suzanne Lentzsch, MD, PhD, has disclosed that she has received consulting fees from Amgen, Bristol-Myers Squibb, and Caelum Biosciences and has ownership interest in Caelum Biosciences.

Faculty Disclosure

Primary Author

Ajai Chari, MD

Director of Multiple Myeloma Program
Professor of Clinical Medicine
University of California- San Francisco
San Francisco, California

Ajai Chari, MD, has disclosed that he has received consulting fees from Amgen, Celgene, Janssen, and Takeda.

Raymond L. Comenzo, MD

Director, Blood Bank and Stem Cell Processing Laboratory
Tufts Medical Center
Professor of Medicine and Pathology
Tufts University School of Medicine
Boston, Massachusetts

Raymond L. Comenzo, MD, has disclosed that he has received consulting fees from Janssen and Prothena.

Jonathan L. Kaufman, MD

Assistant Professor
Winship Cancer Institute
Emory University
Atlanta, Georgia

Jonathan L. Kaufman, MD, has disclosed that he has received consulting fees from AbbVie, Amgen, Roche, Seattle Genetics, and Sutro and has served on the data and safety monitoring committee for Incyte, Pharmacyclics, and TG Therapeutics.

Amrita Krishnan, MD, FACP

Director 
Judy Bernard Briskin Center for Myeloma
Executive Director
Professor
Hematology City of Hope Irvine
Duarte, California

Amrita Krishnan, MD, FACP, has disclosed that she has received consulting fees from Adaptive Biotechnologies, Celgene, Janssen, and Kite Pharma; has received fees for non-CME/CE services received directly from a commercial interest or their agents (eg, speaker bureaus) from Celgene, Janssen, Onyx, and Takeda; and has ownership interest in Celgene.

Staff Disclosure

Staff

Terrence Fagan,

Associate Scientific Director

Terrence Fagan has no real or apparent conflicts of interest to report.

Gordon Kelley,

Clinical Editor
Clinical Care Options, LLC

Gordon Kelley has no real or apparent conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no real or apparent conflicts of interest to report.

Kristen Rosenthal, PhD

Clinical Editor

Kristen Rosenthal, PhD, has no real or apparent conflicts of interest to report.

Additional Information

Program Medium

This program has been made available online.

Participation in this self-study activity should be completed in approximately hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from March 09, 2018, through March 08, 2019:

1. Register online at httpProgram Medium

This program has been made available online.

 

Goal


The goal of this activity is to improve participants’ competence in providing optimal care for patients with multiple myeloma.

Goal


The goal of this activity is to improve participants’ competence in providing optimal care for patients with multiple myeloma.